BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 82.44 USD | -1.62% |
|
+1.89% | -14.50% |
Financials (USD)
| Sales 2024 * | 2.74B | Sales 2025 * | 3.09B | Capitalization | 15.91B |
|---|---|---|---|---|---|
| Net income 2024 * | 359M | Net income 2025 * | 495M | EV / Sales 2024 * | 5.56 x |
| Net cash position 2024 * | 698M | Net cash position 2025 * | 1.34B | EV / Sales 2025 * | 4.72 x |
| P/E ratio 2024 * |
46.2
x | P/E ratio 2025 * |
32.9
x | Employees | 3,401 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioMarin Pharmaceutical Inc.
More recommendations
More press releases
More news
| 1 day | -1.62% | ||
| 1 week | +1.89% | ||
| Current month | +2.08% | ||
| 1 month | -5.00% | ||
| 3 months | -6.02% | ||
| 6 months | +3.58% | ||
| Current year | -14.50% |
1 week
80.50
85.04
1 month
80.5093.36
Current year
80.5099.25
1 year
76.0299.56
3 years
70.73117.77
5 years
62.88131.95
10 years
55.36151.75
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
| Director/Board Member | 70 | 05-05-15 | |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.45% | 1 M€ | -4.80% | - | |
| 1.79% | 0 M€ | 0.00% | - | |
| 1.59% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 82.44 | -1.62% | 1 632 780 |
| 24-05-02 | 83.8 | +0.56% | 1,221,297 |
| 24-05-01 | 83.33 | +3.18% | 1,881,895 |
| 24-04-30 | 80.76 | -1.67% | 2,018,244 |
| 24-04-29 | 82.13 | +1.51% | 2,008,727 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotes
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
83.8
USD
Average target price
110
USD
Spread / Average Target
+31.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.50% | 15.91B | |
| -3.79% | 87.06B | |
| +1.45% | 40.25B | |
| -15.94% | 31.09B | |
| +52.66% | 24.74B | |
| -9.12% | 11.96B | |
| -14.38% | 11.92B | |
| -42.56% | 11.61B | |
| +4.87% | 8.73B | |
| -4.33% | 8.69B |
- Stock Market
- Equities
- BMRN Stock
